Biomarkers in Samples of Bone Marrow From Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is looking at bone marrow samples from patients with acute myeloid leukemia.
Genetic: DNA analysis
Genetic: gene rearrangement analysis
Genetic: microarray analysis
Genetic: polymerase chain reaction
Other: immunological diagnostic method
Other: laboratory biomarker analysis
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||MLL Rearrangements in Acute Myeloid Leukemia: A Pilot Project to Expand and Study MLL-ENL in NOD SCID Gamma Mice|
- Successful transplantation of human acute myeloid leukemia (AML) cells into immunocompromised mice for the purpose of expansion of the cells [ Designated as safety issue: No ]
- Identification of the locations of the protein complexes [ Designated as safety issue: No ]
- Interactions of the SEC and DotCom complexes in human leukemia samples [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
|Study Start Date:||February 2011|
|Estimated Primary Completion Date:||January 2100 (Final data collection date for primary outcome measure)|
- To successfully transplant human acute myeloid leukemia (AML) cells into immunocompromised mice for the purpose of expansion of the cells.
- To harvest the cells and use chromatin immunoprecipitation (ChIP) methods to identify the locations of the protein complexes on the genome.
- To study the interactions of the Super Elongation Complex (SEC) and Dot1 Complex (DotCom) complexes in human leukemia samples.
- To compare the genomic targets of the complexes formed by MLL-ENL chimeras to non-MLL-rearranged leukemia samples to normal controls.
OUTLINE: Cryopreserved cells are implanted into NOD SCID gamma mice, expanded, harvested, and studied by chromatin immunoprecipitation (ChIP) methods (using antibodies to ENL, Af9, and AF10). Results are then analyzed by PCR, DNA sequencing, and/or microarray analysis.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01290107
|Principal Investigator:||Eric Guest, MD||Children's Mercy Hospital|